Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology
Disease Category: Arthritis and Arthritic Pain

Trial Information

Bothered by Arthritis? Concerned about Heart Disease? Learn about a new research study especially for patients with arthritis who have or are at risk for heart disease.

The PRECISION Study is a research study that will compare 3 approved medicines commonly used to treat pain in people with have osteoarthritis (OA) or rheumatoid arthritis (RA. the 3 medicines are Celecoxib (Celebrex), Ibuprofen (Advil or Motrin), and Naproxen (Aleve)). All 3 drugs are approved pain relievers called Nonsteroidal anti-inflammatory drugs or NSAIDs. Doctors refer to ibuprofen and naproxen as traditional NSAIDS, but they refer to Celebrex as a COX-2 inhibitor. That's because Celebres blocks (or inhibits) a certain enzyme in the body called COX-2 that causes pain and inflammation.

Recently, there have been some questions raised about the safety of both COX-2-selective inhibitors and traditional NSAIDs in people who have or are at high risk for heart disease. The PRECISION Study will help answer these questions. The study will help doctors know more about the long-term safety of these medicines on the heart. The PRECISION Study will help provide the information doctors need to choose the most appropriate pain reliever for their patients with OA or RA who have or are at high risk for heart disease.

Patient Inclusion Criteria:

• 18 years of age or older
• have had OA or RA for at least 6 months
• Have been prescribed regular medication for your OA or RA pain for at least 6 months
• Have or be at high risk for heart disease (for example, if you've had a heart attack, stroke, or have diabetes). Your doctor can tell you if you are at high risk for heart disease

Patient Exclusion Criteria:

• Are pregnant or planning to become pregnant or are nursing a baby
• Have had a heart attack, stroke, heart surgery, or any major surgery within 3 months before joining study
• Are scheduled to have surgery during the study
• Have been treated for ulcers within 60 days prior to joining the study
• Have a history of intestinal blockage or gastric bleeding within 6 months prior to joining the study
• Have inflammatory bowel disease, active disease of the stomach, intestines, liver, kidney, a blood clotting disorder, or cancer
• Need and are taking more than 325 mg of aspirin each day

Chip Pemberton, Patient Recruitment Manager
Metroplex Clinical Research Center
5939 Harry Hines Blvd., Suite 441, POB - 2
Dallas, TX 75235
Phone: 214-424-0407
Fax: 214-879-8794
EMail: cpemberton@mcrcdallas.com

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.